Macrogen said Monday that it has signed a business agreement with Myongji Medical Foundation to expand the clinical application of disease management based on genome information.
|Macrogen CEO Suh Jeong-sun and Myongji Medical Foundation Chairman Lee Wang-jun pose after signing a business agreement on Monday|
Under the agreement, the two sides are expected to cooperate with clinical trials of chemotherapeutic treatment such as anti-cancer virus treatment and cell therapy, which is strategically promoted by Myongji Medical Foundation 명지의료재단, by using Macrogen’s genetic analysis technology.
Macrogen 마크로젠 also plans to establish a clinical research and service system that can apply the genome information-based disease management protocol for various diseases such as cancer and rare diseases in early clinical trials.
“We are pleased to cooperate with the Myongji Medical Foundation, which is pioneering new medical technologies such as immunotherapy and cell therapy to integrate treatment for cancer patients, in the field of genome information based disease management,” said Suh Jeong-sun 서정선, CEO of Macrogen.
The collaboration between the two organizations will lead to a platform for more effective management of various diseases, including cancer, in clinical settings, he added.
Myongji Medical Foundation also showed enthusiasm for the cooperative agreement.
“We expect this agreement will strengthen research and business activities in the field of cancer treatment and cell therapy,” said Lee Wang-jun 이왕준, chairman of the Myongji Medical Foundation.
<© Korea Biomedical Review, All rights reserved.>